<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00010140</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068450</org_study_id>
    <secondary_id>ICCG-C/14/96</secondary_id>
    <secondary_id>EU-20040</secondary_id>
    <nct_id>NCT00010140</nct_id>
  </id_info>
  <brief_title>Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer</brief_title>
  <official_title>A Multicenter Randomized Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin in Node Positive Postmenopausal Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Collaborative Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Hormone therapy using tamoxifen may fight breast cancer by blocking&#xD;
      the uptake of estrogen by the tumor cells. Combining chemotherapy with hormone therapy may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of epirubicin and tamoxifen&#xD;
      with or without docetaxel in treating postmenopausal women who have breast cancer that has&#xD;
      spread to the lymph nodes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the impact of adjuvant epirubicin with or without docetaxel and concurrent or&#xD;
           sequential tamoxifen on time to relapse and overall survival in postmenopausal women&#xD;
           with node-positive breast cancer.&#xD;
&#xD;
        -  Compare the toxic effects of these regimens in this patient population.&#xD;
&#xD;
        -  Compare the quality of life in terms of shift in long term toxicity and differences in&#xD;
           recuperation in women treated with these regimens.&#xD;
&#xD;
        -  Compare the incidence of thromboembolic events during the first 9 months of study and&#xD;
           the influence of such events on compliance in women treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center. Patients are randomized to one of two adjuvant chemotherapy treatment&#xD;
      arms within 30 days after surgery.&#xD;
&#xD;
        -  Arm I: Patients receive adjuvant epirubicin IV on days 1 and 8. Treatment continues&#xD;
           every 28 days for 6 courses.&#xD;
&#xD;
        -  Arm II: Patients receive adjuvant epirubicin IV on days 1 and 8. Treatment continues&#xD;
           every 28 days for 3 courses. Patients then receive docetaxel IV over 1 hour on day 1.&#xD;
           Treatment continues every 21 days for 3 courses.&#xD;
&#xD;
      Patients may be further randomized to one of two tamoxifen arms. Patients not randomized to&#xD;
      the tamoxifen arms receive oral tamoxifen daily for 5 years concurrently with adjuvant&#xD;
      chemotherapy.&#xD;
&#xD;
        -  Arm I: Patients receive tamoxifen as above concurrently with adjuvant chemotherapy.&#xD;
&#xD;
        -  Arm II: Patients receive sequential tamoxifen as above after completion of adjuvant&#xD;
           chemotherapy.&#xD;
&#xD;
      Quality of life is assessed at baseline, 9 months, 2 years, and then at 5 years.&#xD;
&#xD;
      Patients are followed at 9 months, 1 year, every 4 months for 1 year, every 6 months for 2&#xD;
      years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 800 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 1997</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of thromboembolic events during the first 9 months after randomization</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven node-positive breast cancer&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
               -  Last menstrual period more than 12 months before initial surgery OR&#xD;
&#xD;
               -  Any age with prior bilateral oophorectomy OR&#xD;
&#xD;
               -  Age 50 or over with prior hysterectomy without oophorectomy (unrelated to&#xD;
                  malignancy)&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO (ECOG) 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm3 OR&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT and SGPT no greater than 1.5 times normal&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 1.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 times normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of significant angina, congestive heart failure, or myocardial infarction&#xD;
             within the past year&#xD;
&#xD;
          -  No clinically significant arrhythmias or uncontrolled hypertension&#xD;
&#xD;
          -  LVEF normal by MUGA, LV gated scan, or echocardiogram&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent serious illness&#xD;
&#xD;
          -  No other prior or concurrent malignancy except adequately treated squamous cell or&#xD;
             basal cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Charles Coombes, MD, MRCP, FRCP, PhD, FMedSci</last_name>
    <role>Study Chair</role>
    <affiliation>Hammersmith Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

